IOVA - Iovance up 13% on completing Biologics License Application submission for lifileucel

2023-03-24 18:22:48 ET

• Iovance Biotherapeutics ( NASDAQ: IOVA ) is up 13% in after-hours trading Friday after reporting it has completed its rolling Biologics License Application for lifileucel for melanoma.
• Lifileucel, a tumor infiltrating lymphocyte therapy, is under investigation for patients with advanced melanoma that have failed on anti-PD-1/L1 therapy and targeted therapy.
• There are no approved treatments for melanoma in this setting .
• Read why Seeking Alpha contributor BioSci Capital Partners reiterated a strong buy rating for Iovance ( IOVA ) in February.

For further details see: